Author details

Full Name

Sergey Popov

Affiliation

ORCID

Career Start Year

2009

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
31701492	Loss of SPINT2 expression frequently occurs in glioma, leading to increased growth and invasion via MMP2.	Cellular oncology (Dordrecht)	2020
32238360	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes.	Cancer Discov	2020
31098401	ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma.	Commun Biol	2019
30408319	The effect of preoperative chemotherapy on histological subtyping and staging of Wilms tumors: The United Kingdom Children's Cancer Study Group (UKCCSG) Wilms tumor trial 3 (UKW3) experience.	Pediatr Blood Cancer	2019
30983144	Rodent burrow network dynamics under human-induced landscape transformation from desert to steppe in Kalmykian rangelands.	Integrative Zoology	2019
29160922	IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance.	Journal of Pathology	2018
29967352	Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells.	Nat Med	2018
29348602	The ten-year evolutionary trajectory of a highly recurrent paediatric high grade neuroepithelial tumour with MN1:BEND2 fusion.	Scientific Reports	2018
26957305	Molecular Diagnostic and Prognostic Subtyping of Gliomas in Tunisian Population.	Molecular Neurobiology	2017
28966033	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma.	Cancer Cell	2017
27671990	Investigating intracranial tumour growth patterns with multiparametric MRI incorporating Gd-DTPA and USPIO-enhanced imaging.	NMR in Biomedicine	2016
27197232	p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.	Cancer Research	2016
27432915	Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.	J Clin Oncol	2016
27333041	Intra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications.	EBioMedicine	2016
26597605	Adult recurrent pilocytic astrocytoma: Clinical, histopathological and molecular study.	Neurochirurgie	2015
25672978	Exploring the biomechanical properties of brain malignancies and their pathologic determinants in vivo with magnetic resonance elastography.	Cancer Research	2015
25749049	Multiple mechanisms of MYCN dysregulation in Wilms tumour.	Oncotarget	2015
25763109	Comparative methylome analysis identifies new tumour subtypes and biomarkers for transformation of nephrogenic rests into Wilms tumour.	Genome Med	2015
26514459	Meningeal Hemangiopericytomas and Meningomas: a Comparative Immunohistochemical and Genetic Study.		2015
25134821	Methylome analysis identifies a Wilms tumor epigenetic biomarker detectable in blood.	Genome Biol	2014
25313908	TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.	PLoS One	2014
24992576	Habitat selection response of small pelagic fish in different environments. Two examples from the oligotrophic Mediterranean Sea.	PLoS ONE	2014
23451042	IDH1-associated primary glioblastoma in young adults displays differential patterns of tumour and vascular morphology.	PLoS ONE	2013
23990986	Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.	PLoS ONE	2013
24158110	Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.	Neuro-Oncology	2013
23308219	miRNA profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema.	PLoS One	2013
23387809	Bilateral wilms tumor with TP53-related anaplasia.	Pediatr Dev Pathol	2013
23135775	Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma.	Journal of Neuro-Oncology	2013
23169794	Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.	Radiology	2013
23539269	Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN.	Cancer Discov	2013
22529373	Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition.	Proceedings of the National Academy of Sciences of the United States of America	2012
22311673	Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity.	Cancer Research	2012
21637783	Microsatellite instability in pediatric high grade glioma is associated with genomic profile and differential target gene inactivation.	PLoS ONE	2011
21054158	Renal tumors in children aged 10-16 Years: a report from the United Kingdom Children's Cancer and Leukaemia Group.	Pediatr Dev Pathol	2011
21659463	Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRÎ±/Î².	Molecular Cancer Therapeutics	2011
20457619	Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma.	Mol Cancer Ther	2010
20332316	Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.	Clin Cancer Res	2010
20339555	A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion.	PLoS ONE	2010
19899003	A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity.	Strahlentherapie und Onkologie	2009